Elicio Therapeutics Announces Virtual KOL Event to Discuss AMP-Powered ELI-002 in KRAS Mutation-Driven Pancreatic Cancer Trial

Reuters

2025/06/17

<a href="https://laohu8.com/S/ELTX">Elicio Therapeutics</a> Announces Virtual KOL Event to Discuss AMP-Powered ELI-002 in KRAS Mutation-Driven Pancreatic Cancer Trial

Elicio Therapeutics Inc., a clinical-stage biotechnology company, has announced a virtual key opinion leader event scheduled for June 25, 2025, to discuss its lead product candidate, ELI-002. This AMP-powered therapeutic vaccine is designed to address the challenges of immune evasion in the treatment of mutant-KRAS (mKRAS) driven pancreatic ductal adenocarcinoma (PDAC). The event will feature insights from experts, including Darrell Irvine, Ph.D., and Eileen O'Reilly, M.D., and will cover the proprietary lymph node-targeting amphiphile ("AMP") platform that supports Elicio's novel immunotherapy pipeline. ELI-002 is currently undergoing evaluation in a randomized Phase 2 trial for the adjuvant treatment of mKRAS-driven PDAC. An interim analysis of the study focused on event-driven disease-free survival is anticipated in the third quarter of 2025. A live Q&A session will follow the presentations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elicio Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9469486-en) on June 17, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2544962851"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2544962851\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2544962851?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-17 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2544962851","market":"us","top_or_hot":-1,"title":"Elicio Therapeutics Announces Virtual KOL Event to Discuss AMP-Powered ELI-002 in KRAS Mutation-Driven Pancreatic Cancer Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ELTX\">Elicio Therapeutics</a> Announces Virtual KOL Event to Discuss AMP-Powered ELI-002 in KRAS Mutation-Driven Pancreatic Cancer Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Elicio <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc., a clinical-stage biotechnology company, has announced a virtual key opinion leader event scheduled for June 25, 2025, to discuss its lead product candidate, ELI-002. This AMP-powered therapeutic vaccine is designed to address the challenges of immune evasion in the treatment of mutant-KRAS (mKRAS) driven pancreatic ductal adenocarcinoma (PDAC). The event will feature insights from experts, including Darrell Irvine, Ph.D., and Eileen O'Reilly, M.D., and will cover the proprietary lymph node-targeting amphiphile (\"AMP\") platform that supports Elicio's novel immunotherapy pipeline. ELI-002 is currently undergoing evaluation in a randomized Phase 2 trial for the adjuvant treatment of mKRAS-driven PDAC. An interim analysis of the study focused on event-driven disease-free survival is anticipated in the third quarter of 2025. A live Q&amp;A session will follow the presentations.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elicio Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9469486-en) on June 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Elicio Therapeutics Announces Virtual KOL Event to Discuss AMP-Powered ELI-002 in KRAS Mutation-Driven Pancreatic Cancer Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nElicio Therapeutics Announces Virtual KOL Event to Discuss AMP-Powered ELI-002 in KRAS Mutation-Driven Pancreatic Cancer Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-17 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ELTX\">Elicio Therapeutics</a> Announces Virtual KOL Event to Discuss AMP-Powered ELI-002 in KRAS Mutation-Driven Pancreatic Cancer Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Elicio <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc., a clinical-stage biotechnology company, has announced a virtual key opinion leader event scheduled for June 25, 2025, to discuss its lead product candidate, ELI-002. This AMP-powered therapeutic vaccine is designed to address the challenges of immune evasion in the treatment of mutant-KRAS (mKRAS) driven pancreatic ductal adenocarcinoma (PDAC). The event will feature insights from experts, including Darrell Irvine, Ph.D., and Eileen O'Reilly, M.D., and will cover the proprietary lymph node-targeting amphiphile (\"AMP\") platform that supports Elicio's novel immunotherapy pipeline. ELI-002 is currently undergoing evaluation in a randomized Phase 2 trial for the adjuvant treatment of mKRAS-driven PDAC. An interim analysis of the study focused on event-driven disease-free survival is anticipated in the third quarter of 2025. A live Q&amp;A session will follow the presentations.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elicio Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9469486-en) on June 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B64PRP62.GBP","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250617:nNDLLxZBN:1","article_id":"2544962851","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2544962851","pubTimestamp":1750161639,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Elicio Therapeutics Announces Virtual KOL Event to Discuss AMP-Powered ELI-002 in KRAS Mutation-Driven Pancreatic Cancer Trial. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elicio Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on June 17, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4588":"碎股","BK4007":"制药","NDAQ":"纳斯达克OMX交易所","ELTX":"Elicio Therapeutics","BK4585":"ETF&股票定投概念","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4139":"生物科技","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4112":"金融交易所和数据"},"translate_title":"Elicio Therapeutics宣布举办虚拟KOL活动，讨论KRAS突变驱动的胰腺癌试验中AMP驱动的ELI-002","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"ELTX":0.9},"content_text":"Elicio Therapeutics Announces Virtual KOL Event to Discuss AMP-Powered ELI-002 in KRAS Mutation-Driven Pancreatic Cancer Trial\n    \n\n        Elicio Therapeutics Inc., a clinical-stage biotechnology company, has announced a virtual key opinion leader event scheduled for June 25, 2025, to discuss its lead product candidate, ELI-002. This AMP-powered therapeutic vaccine is designed to address the challenges of immune evasion in the treatment of mutant-KRAS (mKRAS) driven pancreatic ductal adenocarcinoma (PDAC). The event will feature insights from experts, including Darrell Irvine, Ph.D., and Eileen O'Reilly, M.D., and will cover the proprietary lymph node-targeting amphiphile (\"AMP\") platform that supports Elicio's novel immunotherapy pipeline. ELI-002 is currently undergoing evaluation in a randomized Phase 2 trial for the adjuvant treatment of mKRAS-driven PDAC. An interim analysis of the study focused on event-driven disease-free survival is anticipated in the third quarter of 2025. A live Q&A session will follow the presentations.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elicio Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9469486-en) on June 17, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}